131 related articles for article (PubMed ID: 29053776)
1. Who bears the cost of NICE public health recommendations?
Hinde S; Wiyani A; Griffin S; Walker S
Br Med Bull; 2017 Dec; 124(1):113-120. PubMed ID: 29053776
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation and decision making in the UK.
Buxton MJ
Pharmacoeconomics; 2006; 24(11):1133-42. PubMed ID: 17067197
[TBL] [Abstract][Full Text] [Related]
3. Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?
Walley T
CNS Drugs; 2004; 18(1):1-12. PubMed ID: 14731055
[TBL] [Abstract][Full Text] [Related]
4. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
[TBL] [Abstract][Full Text] [Related]
5. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
[TBL] [Abstract][Full Text] [Related]
6. The NICE cost-effectiveness threshold: what it is and what that means.
McCabe C; Claxton K; Culyer AJ
Pharmacoeconomics; 2008; 26(9):733-44. PubMed ID: 18767894
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
Adang E; Voordijk L; Jan van der Wilt G; Ament A
Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
[TBL] [Abstract][Full Text] [Related]
8. Age-related references in national public health, technology appraisal and clinical guidelines and guidance: documentary analysis.
Forrest LF; Adams J; Ben-Shlomo Y; Buckner S; Payne N; Rimmer M; Salway S; Sowden S; Walters K; White M
Age Ageing; 2017 May; 46(3):500-508. PubMed ID: 27989991
[TBL] [Abstract][Full Text] [Related]
9. Making the economic case for prevention--a view from Wales.
Hale J; Phillips CJ; Jewell T
BMC Public Health; 2012 Jun; 12():460. PubMed ID: 22716189
[TBL] [Abstract][Full Text] [Related]
10. Cost-effective public health guidance: asking questions from the decision-maker's viewpoint.
Chalkidou K; Culyer A; Naidoo B; Littlejohns P
Health Econ; 2008 Mar; 17(3):441-8. PubMed ID: 17764094
[TBL] [Abstract][Full Text] [Related]
11. NICE work--providing guidance to the British National Health Service.
Rawlins MD
N Engl J Med; 2004 Sep; 351(14):1383-5. PubMed ID: 15459297
[No Abstract] [Full Text] [Related]
12. A national Programme Budgeting and Marginal Analysis (PBMA) of health improvement spending across Wales: disinvestment and reinvestment across the life course.
Edwards RT; Charles JM; Thomas S; Bishop J; Cohen D; Groves S; Humphreys C; Howson H; Bradley P;
BMC Public Health; 2014 Aug; 14():837. PubMed ID: 25118054
[TBL] [Abstract][Full Text] [Related]
13. The role of NICE technology appraisal in NHS rationing.
Walker S; Palmer S; Sculpher M
Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
[TBL] [Abstract][Full Text] [Related]
14. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget?
Mauskopf J; Chirila C; Birt J; Boye KS; Bowman L
Health Policy; 2013 Apr; 110(1):49-59. PubMed ID: 23434292
[TBL] [Abstract][Full Text] [Related]
15. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Williams I; McIver S; Moore D; Bryan S
Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
[TBL] [Abstract][Full Text] [Related]
16. Health economic decision-making: a comparison between UK and Spain.
Corbacho B; Pinto-Prades JL
Br Med Bull; 2012 Sep; 103(1):5-20. PubMed ID: 22833571
[TBL] [Abstract][Full Text] [Related]
17. UK budgetary systems and new health-care technologies.
McGuire A; Litt M
Value Health; 2003; 6 Suppl 1():S64-73. PubMed ID: 12846927
[TBL] [Abstract][Full Text] [Related]
18. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
Sculpher M; Palmer S
Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
[TBL] [Abstract][Full Text] [Related]
19. NICE at 10 years: new challenges ahead.
Littlejohns P
Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):151-6. PubMed ID: 19402803
[TBL] [Abstract][Full Text] [Related]
20. A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
Jiang Y; Gauthier A; Keeping S; Carroll S
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):901-11. PubMed ID: 25186657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
